These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8781425)

  • 1. Clearance of normal and type 2A von Willebrand factor in the rat.
    Stoddart JH; Andersen J; Lynch DC
    Blood; 1996 Sep; 88(5):1692-9. PubMed ID: 8781425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease.
    Schneppenheim R; Budde U; Obser T; Brassard J; Mainusch K; Ruggeri ZM; Schneppenheim S; Schwaab R; Oldenburg J
    Blood; 2001 Apr; 97(7):2059-66. PubMed ID: 11264172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease.
    Tjernberg P; Vos HL; Spaargaren-van Riel CC; Luken BM; Voorberg J; Bertina RM; Eikenboom JC
    Thromb Haemost; 2006 Dec; 96(6):717-24. PubMed ID: 17139364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of type 2b von Willebrand disease mutations: implications for the mechanism of von Willebrand factor binding to platelets.
    Cooney KA; Ginsburg D
    Blood; 1996 Mar; 87(6):2322-8. PubMed ID: 8630394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased susceptibility of recombinant type 2A von Willebrand factor mutant A1500E to proteolysis by ADAMTS13].
    Zhang JY; Su J; Ma ZN; Dong NZ; Wang YC; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):169-72. PubMed ID: 22781599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor.
    O'Sullivan JM; Aguila S; McRae E; Ward SE; Rawley O; Fallon PG; Brophy TM; Preston RJ; Brady L; Sheils O; Chion A; O'Donnell JS
    J Thromb Haemost; 2016 Dec; 14(12):2446-2457. PubMed ID: 27732771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
    Eikenboom JC; Matsushita T; Reitsma PH; Tuley EA; Castaman G; Briët E; Sadler JE
    Blood; 1996 Oct; 88(7):2433-41. PubMed ID: 8839833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
    Englender T; Lattuada A; Mannucci PM; Sadler JE; Inbal A
    Blood; 1996 Apr; 87(7):2788-94. PubMed ID: 8639896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
    Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
    Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
    Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
    Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired dimerization of von Willebrand factor subunit due to mutation A2801D in the CK domain results in a recessive type 2A subtype IID von Willebrand disease.
    Hommais A; Stépanian A; Fressinaud E; Mazurier C; Pouymayou K; Meyer D; Girma JP; Ribba AS
    Thromb Haemost; 2006 May; 95(5):776-81. PubMed ID: 16676067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins.
    Bodó I; Katsumi A; Tuley EA; Eikenboom JC; Dong Z; Sadler JE
    Blood; 2001 Nov; 98(10):2973-9. PubMed ID: 11698279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
    Casonato A; Sartorello F; Cattini MG; Pontara E; Soldera C; Bertomoro A; Girolami A
    Blood; 2003 Jan; 101(1):151-6. PubMed ID: 12393698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.